Literature DB >> 7881416

Evidence for recessive as well as dominant forms of startle disease (hyperekplexia) caused by mutations in the alpha 1 subunit of the inhibitory glycine receptor.

M I Rees1, M Andrew, S Jawad, M J Owen.   

Abstract

Startle disease, or hyperekplexia, is characterized by an exaggerated startle reflex and neonatal hypertonia. An autosomal dominant form of the disorder is associated with mutations in the same codon of the alpha 1 subunit of the inhibitory glycine receptor (GLRA 1) resulting in the substitution of an uncharged amino acid for Arg271 in the mature protein. However, recessive transmission is seen in the mouse mutant spasmodic which resembles startle disease phenotypically and is also associated with mutations in Glra 1. We have confirmed the finding of Arg271 mutations in individuals with startle disease in a UK family showing autosomal dominant transmission. In addition we describe an apparently sporadic case, the offspring of a consanguineous mating, who is homozygous for a novel mutation (T1112A) in GLRA 1, which results in the substitution of asparagine for isoleucine at position 244 of the mature protein. This suggests that human startle disease can display recessive as well as dominant inheritance resulting from different mutations in GLRA 1.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7881416     DOI: 10.1093/hmg/3.12.2175

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  27 in total

1.  A GLRA1 null mutation in recessive hyperekplexia challenges the functional role of glycine receptors.

Authors:  W Brune; R G Weber; B Saul; M von Knebel Doeberitz; C Grond-Ginsbach; K Kellerman; H M Meinck; C M Becker
Journal:  Am J Hum Genet       Date:  1996-05       Impact factor: 11.025

2.  Hyperekplexia in two siblings.

Authors:  M L Kulkarni; B Kannan; Prakash Mathadh
Journal:  Indian J Pediatr       Date:  2006-12       Impact factor: 1.967

3.  Identification of intracellular and extracellular domains mediating signal transduction in the inhibitory glycine receptor chloride channel.

Authors:  J W Lynch; S Rajendra; K D Pierce; C A Handford; P H Barry; P R Schofield
Journal:  EMBO J       Date:  1997-01-02       Impact factor: 11.598

4.  A novel nonsense autosomal dominant mutation in the GLRA1 gene causing hyperekplexia.

Authors:  Ivan Milenkovic; Alexander Zimprich; Martin Gencik; Kirsten Platho-Elwischger; Stefan Seidel
Journal:  J Neural Transm (Vienna)       Date:  2018-09-04       Impact factor: 3.575

5.  The surface accessibility of the glycine receptor M2-M3 loop is increased in the channel open state.

Authors:  J W Lynch; N L Han; J Haddrill; K D Pierce; P R Schofield
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

Review 6.  Molecular biology of glycinergic neurotransmission.

Authors:  F Zafra; C Aragón; C Giménez
Journal:  Mol Neurobiol       Date:  1997-06       Impact factor: 5.590

7.  Hereditary hyperekplexia caused by novel mutations of GLRA1 in Turkish families.

Authors:  Sandra L Gilbert; Fatih Ozdag; Umit H Ulas; William B Dobyns; Bruce T Lahn
Journal:  Mol Diagn       Date:  2004

8.  A novel mutation (Gln266-->His) in the alpha 1 subunit of the inhibitory glycine-receptor gene (GLRA1) in hereditary hyperekplexia.

Authors:  N Milani; L Dalprá; A del Prete; R Zanini; L Larizza
Journal:  Am J Hum Genet       Date:  1996-02       Impact factor: 11.025

9.  The glycinergic system in human startle disease: a genetic screening approach.

Authors:  Jeff S Davies; Seo-Kyung Chung; Rhys H Thomas; Angela Robinson; Carrie L Hammond; Jonathan G L Mullins; Eloisa Carta; Brian R Pearce; Kirsten Harvey; Robert J Harvey; Mark I Rees
Journal:  Front Mol Neurosci       Date:  2010-03-23       Impact factor: 5.639

10.  Localization of glycine receptors in the human forebrain, brainstem, and cervical spinal cord: an immunohistochemical review.

Authors:  Kristin Baer; Henry J Waldvogel; Richard L M Faull; Mark I Rees
Journal:  Front Mol Neurosci       Date:  2009-11-04       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.